← Evidence library

BIB_176

Robert C et al. Pembrolizumab vs Ipilimumab in Advanced Melanoma — 5-year follow-up (KEYNOTE-006). Lancet Oncology 2019;20(9):1239–1251. PMID 31345627. ORR ~42%, median OS ~33 months, 5-yr OS ~38%. Single-agent pembrolizumab standard for advanced patients unfit for combination. [Tasks: 18] Tier: 1 Grade: A Retrieved: 2026-05-07

Evidence grade

A

Tier

1

Cited by tasks

18

Identifiers

PMID:31345627

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_176/findings.md (research corpus). This page is a short context summary — not individualised medical advice.